Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer - PubMed (original) (raw)

D E B Swinson et al. Br J Cancer. 2004.

Abstract

The epidermal growth factor receptor (EGFR) is commonly expressed in non-small-cell lung cancer (NSCLC) and promotes a host of mechanisms involved in tumorigenesis. However, EGFR expression does not reliably predict prognosis or response to EGFR-targeted therapies. The data from two previous studies of a series of 181 consecutive surgically resected stage I-IIIA NSCLC patients who had survived in excess of 60 days were explored. Of these patients, tissue was available for evaluation of EGFR in 179 patients, carbonic anhydrase (CA) IX in 177 patients and matrix metalloproteinase-9 (MMP-9) in 169 patients. We have previously reported an association between EGFR expression and MMP-9 expression. We have also reported that MMP-9 (P=0.001) and perinuclear (p)CA IX (P=0.03) but not EGFR expression were associated with a poor prognosis. Perinuclear CA IX expression was also associated with EGFR expression (P<0.001). Multivariate analysis demonstrated that coexpression of MMP-9 with EGFR conferred a worse prognosis than the expression of MMP-9 alone (P<0.001) and coexpression of EGFR and pCA IX conferred a worse prognosis than pCA IX alone (P=0.05). A model was then developed where the study population was divided into three groups: group 1 had expression of EGFR without coexpression of MMP-9 or pCA IX (number=21); group 2 had no expression of EGFR (number=75); and group 3 had coexpression of EGFR with pCA IX or MMP-9 or both (number=70). Group 3 had a worse prognosis than either groups 1 or 2 (P=0.0003 and 0.027, respectively) and group 1 had a better prognosis than group 2 (P=0.036). These data identify two cohorts of EGFR-positive patients with diametrically opposite prognoses. The group expressing either EGFR and or both MMP-9 and pCA IX may identify a group of patients with activated EGFR, which is of clinical relevance with the advent of EGFR-targeted therapies.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Kaplan–Meier survival curve and log-rank _P_-value for MMP-9 expression in NSCLC.

Figure 2

Figure 2

Kaplan–Meier survival curve and log-rank _P_-value for pCA IX expression in NSCLC.

Figure 3

Figure 3

Kaplan–Meier survival curve and log-rank _P_-value for EGFR expression in NSCLC.

Figure 4

Figure 4

Survival curves for EGFR expression alone (group 1), EGFR negative (group 2) and coexpression of EGFR with either MMP-9 or CA IX or both (group 3).

Similar articles

Cited by

References

    1. Abdollahi A, Bao R, Hamilton TC (1999) Lot1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein. Oncogene 18: 6477–6487 - PubMed
    1. Bailey LR, Janas M, Schmidt K, Bindsley N, Wolf M, Grous J, Askaa J, Herbst R, Johnson D, Giaccone G (2004) Evaluation of epidermal growth factor receptor (egfr) as a predictive marker in patients with non-small cell lung cancer (nsclc) receiving first-line gentifinib combined with cisplatin based chemotherapy. Proc Am Soc Clin Oncol 23: 618
    1. Clarke K, Smith K, Gullick WJ, Harris AL (2001) Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a pi3 kinase dependent pathway. Br J Cancer 84: 1322–1329 - PMC - PubMed
    1. Cohen S, Carpenter G, King Jr L (1981) Epidermal growth factor-receptor–protein kinase interactions. Prog Clin Biol Res 66: 557–567 - PubMed
    1. Cohen S, Carpenter G, King LJ (1980) Epidermal growth factor receptor-kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255: 4834–4842 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources